Losartan Potassium Tablets, 50 Mg Tablet
Product Images NDC 72162-1697

Product Visual Gallery

This gallery contains 6 technical images submitted to the FDA as part of the official labeling for Losartan Potassium Tablets, 50 Mg (NDC 72162-1697). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Bryant Ranch Prepack, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Figure 1 (Figure1)

A line graph comparing the percentage of patients with primary endpoint events over a 66-month study period for Atenolol and Losartan Potassium. The graph shows the cumulative incidence increasing over time, with Losartan Potassium demonstrating a slightly lower percentage than Atenolol. An adjusted risk reduction of 13% is noted with a p-value of 0.021.*

FDA Label Image

Figure 2 (Figure2)

A line chart comparing the percentage of patients with fatal or non-fatal strokes over 66 months between two groups: one treated with Atenolol (dotted line) and the other with Losartan Potassium (solid line). The graph shows a lower stroke incidence in the Losartan Potassium group with an adjusted risk reduction of 25% (p=0.001). The x-axis represents study months, and the y-axis shows the percentage of patients with stroke.*

FDA Label Image

Figure 3 (Figure3)

A figure titled 'Primary Endpoint Events within Demographic Subgroups' presents hazard ratio forest plots comparing Losartan and Atenolol event rates for primary composite endpoints and stroke (fatal/non-fatal) across subgroups by age, gender, race, isolated systolic hypertension, diabetes, and history of cardiovascular disease. The graph shows event rates and 95% confidence intervals, indicating comparative effects of the two drugs.*

FDA Label Image

Figure 4.jpg (Figure4)

A line graph comparing the percentage of patients with an event over a 48-month period for Losartan Potassium versus placebo. The x-axis represents months and the y-axis shows the percentage of patients with the event. The graph includes a stated risk reduction of 16.1% with a p-value of 0.022.*

FDA Label Image

Label (Lbl721621697)

Label for Losartan Potassium Tablets USP 50 mg by Bryant Ranch Prepack, including product name, strength, and NDC 72162-1697-0. It states package size of 1000 tablets, storage instructions, and manufacturer Jubilant Cadista Pharmaceuticals Inc. Barcode and information for pharmacists also appear.*

FDA Label Image

Losartan Potassium, Usp (Structure)

Chemical structure diagram of losartan potassium, showing its molecular components including a chlorinated imidazole ring, phenyl rings, and potassium ion.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.